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Abstract 
Rationale 
In utero tobacco exposure is associated with reduced infant lung function. Anti-oxidant 
enzymes from the glutathione-s-transferase (GST) family may protect against these lung 
function deficits. 
Objectives: 
(1) Assess the long-term effect of in utero smoke exposure on lung function into adulthood. 
(2) Assess whether GSTT1 and GSTM1 active genotypes have longterm protective effects on 
lung function. 
Methods: 
In this longitudinal study, based on a normal population (n=253), lung function was measured 
during infancy and then at 6, 11, 18 and 24 years. GSTM1 and GSTT1 genotype was analysed 
in a subgroup (n= 179). Lung function was assessed longitudinally from 6 to 24 years (n=144). 
Main Results 
Exposure to maternal in utero tobacco was associated with lower FEV1 and FVC from 6 to 24 
years (mean difference – 3.87% predicted, p=0.021; -3.35% predicted, p=0.035, respectively). 
Among those homozygous for the GSTM1 null genotype, in utero tobacco exposure was 
associated with lower FEV1 and FVC compared with those with no in utero tobacco exposure 
(mean difference -6.2% predicted, p=0.01; -4.7% predicted, p=0.043 respectively). For those 
with GSTM1 active genotype, there was no difference in lung function whether exposed to 
maternal in utero tobacco or not. In utero tobacco exposure was associated with deficits in lung 
function among those with both GSTT1 null and GSTT1 active genotypes. 
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Conclusions 
GST genotypes may have protective effects against the deficits in lung function associated with 
in utero tobacco exposure. This offers potential preventative targets in anti-oxidant pathways 
for at-risk infants of smoking mothers. 
 
 
Abstract Words: 247 
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Introduction: 
The exposure of children’s lungs to tobacco smoke is of grave concern as lungs are particularly 
vulnerable to insult during development. This exposure can occur while still in utero, as 
nicotine and other toxic substances freely pass through the placenta or postnatally in the home 
environment 1.  
Exposure to tobacco smoke antenatally is associated with reduced lung function during infancy 
and childhood 3 4. Both ante- and post-natal smoke exposure are linked to an increase in 
respiratory symptoms throughout childhood and adolescence 2.  
We have previously shown that airway function measurements track from infancy into early 
adulthood indicating an inherent airway structure is laid down early in lung development, while 
measurements of adult lung size were independent of infant lung function, suggesting lung 
growth is modifiable by external factors. 
Gene-environment interactions modulate the effects of in utero smoke (ITS) exposure on 
respiratory outcomes in childhood and fetal anti-oxidants may play a role in protecting the 
developing lungs. Activity levels of glutathione s-transferases (GST), a family of enzymes 
involved in the detoxification of xenobiotics, vary based on genotype, with homozygous 
deletions of the GSTT1 and GSTM1 genes associated with absent function of that particular 
enzyme 5 6. Among those exposed to ITS, GST active genotypes are linked to higher infant lung 
function when compared with those with the null genotype, as previously reported in this cohort 
7. GST null genotypes are associated with increased risk of childhood asthma compared with 
those with active genotypes, particularly in the context of passive smoke exposure, suggesting 
an increased vulnerability to the detrimental effects of tobacco smoke 8-10.  
We hypothesised that the negative effect of ITS exposure on lung function would persist into 
adulthood but that this effect would be lessened for those with higher levels of innate 
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detoxification enzymes. Our aim was to: (1) assess the long-term effects of both ante and post-
natal smoke exposure on lung function, as a measure of lung development; and (2) assess 
whether GSTT1 and GSTM1 active genotypes are protective against the effects of in utero 
tobacco smoke on lung function through into adulthood. 
 
 
Methods and Materials: 
The Perth Infant Asthma Follow study was established in 1987. Over 24 months, 253 subjects 
were recruited antenatally from an urban maternity hospital in Perth, Western Australia. There 
was no preselection based on family history of asthma or atopy. Recruitment details have been 
published previously 11. Infants were excluded if they were born premature <37 weeks 
gestation, had any major congenital abnormality or had any significant respiratory illnesses in 
the first month of life. 
Detailed antenatal smoking history during each trimester of the pregnancy was collected from 
both parents. Fetal in utero tobacco exposure was classified as positive for maternal or paternal 
exposure if that parent smoked at all during the pregnancy. Subjects could be positive for both 
maternal and paternal in utero tobacco exposure. Subjects were classified as negative for any 
ITS exposure if neither parent smoked at all during the pregnancy.  
Urinary cotinine, a byproduct of nicotine metabolism, was measured in a subgroup of infants 
at birth (n=85). 
Subjects or their parents also completed a questionnaire at each follow-up assessment12. This 
included questions on history of physician-diagnosed asthma and tobacco smoke exposure in 
the household. “Postnatal smoke exposure only” was classified as a positive response to post-
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natal smoke exposure at either 1, 6 or 11 years of age and no history of maternal in utero smoke 
exposure. “Incomplete postnatal data” was recorded if there was less than 2 postnatal 
assessments.  
The participants performed lung function testing at regular intervals from infancy through to 
young adulthood at 1 month, 6 months, 12 months, 6, 11, 18 and 24 years of age.  
The rapid thoraco-abdominal compression technique during tidal breathing of sedated infants 
was used during infant lung function testing 13. The interaction between in utero tobacco 
exposure and GST genotype on infant lung function in this cohort has been published 
previously 7.  
Spirometry was performed at each assessment from 6 to 24 years14. FEV1, FVC, FEF25-75% 
and FEV1/FVC were recorded and converted into percent predicted scores based on sex, age, 
height and ethnicity using GLI reference values15. 
GST genotyping analysis was performed on blood samples taken at either the 6 or 11 year 
assessments. GSTT1 and GSTM1 deletion polymorphisms were identified by polymerase chain 
reaction (PCR) methods as previously described in detail 7 16. A subset of specimens had 
genotype results confirmed by PCR with a second set of primers 7. CYP1A1 primers were used 
as a positive control for each PCR performed. Those who were homozygous for the GST null 
genes were classified as GST null and those who were either heterozygous or homozygous for 
non-null GST genotype was classified as GST active. 
The study was approved by the Western Australian Child and Adolescent Health Service 
Human Research Ethics Committee (2054EP). Parents, or subjects when appropriate (aged > 
18 years), signed informed consent forms for each assessment. 
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Statistical analysis: 
Comparisons between the participants seen at each assessment was analysed by Pearson’s chi-
square for categorical variables and independent t-test for continuous variables. 
Mean difference in cotinine levels between infants whose mothers reported smoking at 
recruitment and infants whose mothers reported not smoking at recruitment were measured 
using the Mann Whitney U test. 
In the longitudinal analysis, the link between tobacco smoke exposure or GST genotype and 
lung function from 6 to 24 years were assessed by generalised estimating equations. These 
equations adjust for inherent covariance in each subject 17.  
Mean lung function results (FEV1, FVC, FEF25-75% and FEV1/FVC% predicted) from the 6, 
11, 18 and 24 year assessments were the longitudinal outcome variables for each participant. 
Maternal ITS, paternal ITS and postnatal tobacco exposure only were all assessed separately 
and compared with no in utero smoke exposure.  
In order to assess the effect of GST polymorphisms on lung function in the context of in utero 
tobacco exposure, we then split the group into GST genotype i.e firstly GSTT1 null versus 
GSTT1 active and then GSTM1 null and GSTM1 active and applied the generalised estimating 
equations. Mean longitudinal lung function (% predicted) for those exposed and not exposed 
to maternal ITS in each subgroup were included as outcome variables. 
Two-sided p value <0.05 determined statistical significance. 
This study had a power of 0.813 to reject the null hypothesis of no significant difference in 
FEV1 between GSTT1 null and GSTT1 non-null genotype groups based on 411 assessments, if 
the real difference between groups was 5% predicted, with standard deviation of 12% 
predicted. The Type I error probability associated with this test of this null hypothesis is 0.05. 
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Analyses were performed using SPSS Statistics for Windows, version 24.0. (2016, Armonk, 
NY: IBM Corp).  
 
Results: 
General 
Of the original 253 subjects recruited, smoking history during the pregnancy was collected 
from 252 mothers and 240 fathers. Eighty five subjects (34%) reported exposure to maternal 
smoking during the pregnancy and ninety-four (39%) reported exposure to paternal smoking 
during the pregnancy. A further 47 subjects  out of 129 with no maternal ITS exposure and at 
least 2 postnatal assessments, reported exposure to post-natal tobacco smoke in the home, with 
82 subjects reporting no pre or post natal smoke exposure and incomplete post-natal exposure 
data on the remaining 38 subjects.  
Lung function testing was performed on 110 subjects at 6 years, 183 at 11 years, 141 at 18 
years and 118 subjects at 24 years. Comparison of subject characteristics at each assessment 
have previously been published18. The only significant difference between the original cohort 
and those seen at follow up was less parental ITS exposure in those seen at later follow ups 
(54% ITS exposure in original cohort; 45% of those seen at 18 years; 43% of those seen at 24 
years). GSTT1 and GSTM1 genotyping was performed on 179 subjects and the frequency of 
each genotype is presented in table 1. There were 144 subjects with 443 assessments included 
in the longitudinal analysis of smoke exposure, and 128 subjects with 411 assessments in the 
longitudinal analysis of GST genotype and smoke exposure. 
Cotinine levels and maternal smoke exposure 
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Neonatal cotinine levels were higher amongst infants whose mothers reported smoking at 
recruitment during pregnancy (n=25; mean 75.3ng/ml creatinine, SD 57.7), than those whose 
mothers reported no smoking at recruitment (n=60; mean 9.3ng/ml creatinine, SD 30.5), 
p<0.001. 
 
In utero tobacco smoke exposure and lung function 
Exposure to maternal ITS was associated with significantly lower FEV1 and FVC from 6 to 24 
years of age (mean difference – 3.87% predicted, p=0.021, and -3.35% predicted, p=0.035, 
respectively) Figure 1; supplementary table 1. Exposure to maternal ITS was not associated 
with a difference in either FEV1/FVC or FEF25-75%. Neither exposure to paternal ITS nor 
postnatal tobacco exposure only were associated with significant changes in lung function from 
6 to 24 years. Therefore, further reference to ITS refers to maternal ITS exposure only, 
independent of post-natal smoke exposure. 
 
GST polymorphisms and in utero tobacco smoke exposure 
There was no difference in lung function from 6 to 24 years of age between the GST null and 
active genotype groups (supplementary table 2).  
Among those with the GSTM1 active genotype, maternal ITS exposure was not associated with 
any significant difference in lung function from 6 and 24 years of age. Among those with the 
GSTM1 null genotype, ITS exposure was associated with a lower FEV1 and FVC compared 
with those with no ITS exposure (mean difference FEV1 -6.2% predicted, p=0.01; mean 
difference FVC -4.7% predicted, p=0.043) (table 2; figure 2) 
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Among those with the GSTT1 active genotype, FEV1 and FVC were lower in those exposed to 
maternal ITS compared with no maternal ITS exposure (mean difference FEV1= -4.05% 
predicted, p=0.034; FVC= -3.7% predicted, p=0.037 respectively). Among those with the 
GSTT1 null genotype, FEV1 and FEF25-75% were lower in those exposed to ITS, compared 
with no ITS (mean difference FEV1 = - 10.29% predicted, p=0.021; mean difference FEF25-
75% = -15.2% predicted, p=0.008). (table 2; figure 2). However, only three subjects with 
exposure to maternal ITS had the GSTT1 null genotype and all three also had the GSTM1 null 
genotype. 
 
 
Discussion: 
This longitudinal, birth-cohort study of lung function confirms that maternal ITS exposure is 
linked to lower lung function from infancy to early adulthood, and establishes an important 
new finding: the major effect of in utero smoke exposure is on lung size rather than airway size 
or function. This conclusion stems from the finding that the deficits in future respiratory 
function were specifically in FEV1 and FVC and not FEF25-75% or FEV1/FVC. A previous 
study from this cohort revealed that variables reflecting airway function, V’maxFRC in infancy 
and FEF 25-75% and FEV1/FVC thereafter, track from infancy into early adulthood. Together 
these findings provide compelling evidence suggesting that the foundations of airway structure 
are laid down during antenatal development, persist throughout childhood and are relatively 
resistant to environmental insults. In contrast, lung size in childhood, as measured by FEV1 and 
FVC, had no correlation with infant airway function, but did correlate with tobacco smoke 
exposure, implying that lung size (perhaps as a reflection of alveolar number) is vulnerable to 
external, environmental factors.   
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A further important finding was evidence suggesting that the presence of active glutathione s-
transferase enzymes provide longterm protection from the damage caused by maternal ITS 
exposure. In particular, the functional GSTM1 active genotype appears to have this protective 
effect. Maternal ITS was only associated with deficits in lung function up to adulthood for 
those with the GSTM1 null genotype and not for those with the GSTM1 active genotype. The 
functional GSTT1 active genotype did not appear to share this degree of protective effect, as 
those with this genotype still had significant deficits in lung function if exposed to maternal 
ITS compared with those with no ITS exposure. However, the difference between those 
exposed and not exposed was smaller than among the GSTT1 null genotype group suggesting 
that GSTT1 active may still provide a degree of protection, although not enough to fully 
overcome the damage associated with ITS exposure. GSTT1 may be of more importance in 
protection very early on, as in a previous study from this cohort, GSTT1 active  genotype was 
associated with higher lung function during infancy mong those exposed to maternal ITS than 
the GSTT1 null group 7.  
Glutathione s-transferase is an enzyme which catalyses the reaction between glutathione and 
electrophilic xenobiotics and reactive oxygen species, making it crucial to the body’s 
detoxification processes19. There are eight classes of cytosolic GST in humans, each with 
several subclasses, which vary in their structure and substrate specificity 20. Although nicotine 
is not metabolised by the GST enzymes, many of the other toxic substances within cigarettes 
are 21 22.  Homozygous GSTM1 and GSTT1 null polymorphisms have been associated with the 
development of asthma in childhood, thought to be due to an increase in oxidative stress, 
although they are not related to asthma severity (turner new paper). Adjusting for confounding 
variables during childhood such as tobacco exposure and environmental pollution is difficult 
and may be the reason results from previous studies have not been convincing 23. GSTM1 and 
GSTT1 null genotypes have both been found to be strong predictors of COPD in adult 
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females24. The GSTM1 null genotype is also associated with reduced lung function growth in 
children, while the GSTT1 null genotype is associated with accelerated lung function decline 
in adult males25 26. However, these studies did not specifically investigate those exposed to 
tobacco smoke in utero, a critical time during lung development and we did not find a link 
between GST genotype and lung function among those not exposed to ITS.  
The GSTT1 null genotype is rarer than the GSTM1 null genotype, affecting only 15% of the 
population. The subject numbers with both GSM1 null genotype and maternal ITS exposure, 
n=3, make definitive statements about this group difficult. However, the length of follow up 
from infancy through into early adulthood in this study is an important advantage, as this spans 
the entire post-natal lung growth phase, to the peak in lung function in early adulthood.  
During the in utero period of organogenesis, the fetus is exposed to the same levels of 
nicotine and other toxic substances as found in the actively-smoking mother, as these toxic 
substances pass freely through the placenta. Cotinine, a by-product of nicotine metabolism, 
can be measured in umbilical cord blood of newborn infants whose mothers smoked during 
pregnancy1. Although the tobacco is not inhaled into the lungs of the fetus, the serum 
exposure to these toxins is associated with reduced lung function when measured in the first 
few days of life, even before any post-natal tobacco smoke expsoure27. Given the negative 
associations between tobacco exposure while pregnant and infant outcomes, pregnant 
mothers may be reluctant to admit smoking to study researchers.  However we collected 
objective evidence of tobacco exposure, with neonatal urinary cotinine levels, which confirm 
the reliability of the parent reported smoking data.  
Interestingly, there was no link between either paternal ITS exposure or postnatal tobacco 
smoke exposure alone, on lung function throughout childhood, suggesting the most 
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significant impact of tobacco exposure on lung function is a dose response effect during the 
in utero developmental phase. 
Children with two hits, a toxic exposure and a genetic vulnerability, are at risk for the largest 
deficits in lung growth during lung development. Our data suggests there is a protective benefit 
in having higher anti-oxidant levels during in utero development and this warrants further 
exploration. Finding a way to protect the lungs during critical periods of development, for 
example with anti-oxidant supplementation or boosting the fetal glutathione pathway, and 
avoiding long-term detrimental consequences could potentially be an important target in 
minimising chronic respiratory morbidity for the children of smoking mothers. 
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Table 1. Prevalence of GST genotypes (n=179) 
  N 
 GSTM1 – 
GSTM1 + 
105 (59%) 
74 (41%) 
 GSTT1 – 
GSTT1 + 
27 (15%) 
152 (85%) 
 GSTM1 -  and GSTT1- 11 (6%) 
– = homozygous null genotype; + = heterozygous or homozygous non-null genotype.  
 
 
 
 
  
 
 
 
Figure 1. Mean lung function from 6-24 years by tobacco smoke exposure. Number of 
subjects=144; number of assessments = 443 
 
Lung function from 6-24 years. % predicted based on GLI reference values. Generalised 
estimating equations. Error bars depicting 95% confidence interval. 
*p=0.021; **p=0.035 
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Table 2. Association between maternal in utero tobacco smoke exposure and lung function 
from 6-24 years, grouped by GST genotype.  
 
  FEV1 % pred 
(95% CI) 
FVC % pred 
(95% CI) 
FEF 25-75% 
pred 
FEV1/FVC % 
pred 
(95% CI) 
GSTM1 null 
 
No ITS 
(n=52) 
102.88 
(100.02 -105.73) 
101.77 
(99.04 – 104.5) 
97.88 
(93 – 102.75) 
100.22 
(98.8 – 101.6) 
Maternal ITS 
(n=23) 
96.7 
(92.92 – 100.49) 
p=0.01 
97.06 
(93.4 – 100.72) 
p=0.043 
90.36 
(83.85 – 96.89) 
p=0.07 
98.88 
(97.0 – 100.8) 
p=0.27 
 
GSTM1 non-
null 
 
No ITS 
(n=41) 
102.56 
(99.51 -105.61) 
102.83 
(99.82 – 105.84) 
95.38 
(90.06 – 100.69) 
98.78 
(96.87 – 100.69) 
 Maternal ITS 
(n=12) 
100.5 
(96.63 – 104.37) 
p=0.41 
 
100.05 
(96.68 – 103.43) 
p=0.229 
92.54 
(85.18 – 99.89) 
p=0.54 
99.78 
(97.48 -102.1) 
p=0.51 
GSTT1 null 
 
No ITS (n=18) 102.26 
(98.64 – 105.88) 
100.44 
 (95.96 – 104.92) 
100.84 
(94.73 – 106.96) 
100.74 
(98.19 – 103.29) 
 Maternal ITS 
(n=3) 
91.94 
(83.98 – 99.9) 
p=0.021 
 
91.74 
(80.78 – 102.7) 
p=0.15 
85.63 
(76.2 – 95.08) 
p=0.008 
99.8 
(95.51– 104.09) 
p=0.71 
 
GSTT1 non-
null 
 
No ITS 
(n=75) 
102.85 
(100.43 – 105.26) 
102.6 
(100.34 – 104.86) 
95.96 
(91.8 – 100.12)  
99.37 
(98.08 – 100.65) 
 Maternal ITS 
(n=32) 
98.8 
(95.94 – 101.67) 
p=0.034 
 
98.9 
(96.32 – 101.4) 
p=0.031 
91.75 
(86.49 -  97.01)  
p=0.22 
99.19 
(97.63 – 100.75) 
p=0.86 
Mean difference in % predicted lung function for those exposed to maternal in utero tobacco 
smoke, compared with not exposed to maternal in utero tobacco smoke, by GST genotype. 
Number of subjects=128; number of assessments = 411Bold font indicates p<0.05 
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Figure 2. Mean lung function from 6-24 years for GST null versus non-null genotype, 
by maternal ITS exposure  
  
 
 
 
Mean lung function longitudinally from 6-24 years, % predicted based on GLI reference 
range.  *p<0.05 ; ** p≤ 0.01 
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Supplementary Table 1: Lung function from 6-24 years by passive smoke exposure  
 
 FEV1% 
predicted 
FVC 
% predicted 
FEF25-75% 
% predicted 
FEV1/FVC 
% predicted 
No passive 
smoke exposure 
102.37 
(99.83 – 104.91) 
101.57 
(99.16 – 103.97) 
96.02 
(91.67 – 100.36) 
99.93 
(98.56 - 101.31) 
Maternal ITS 98.55 
(95.88 – 101.22) 
 
98.45 
(95.97 – 100.93) 
91.94 
(87.21 – 96.67) 
99.36 
(97.95 – 100.77) 
Paternal ITS 100.95 
(98.34 – 103.56) 
 
100.84 
(98.29 – 103.39) 
95.18 
(90.89 – 99.47) 
99.29 
(98.01 – 100.57) 
Postnatal smoke 
exposure only 
102.08 
(97.87 – 106.29) 
102.44 
(98.23 – 106.65) 
96.2 
(89.46 – 102.9) 
98.69 
(96.5 – 100.87) 
No passive smoke exposure – no in utero or postnatal tobacco smoke exposure from either 
parent or household member; Maternal ITS – mother smoked at all during the pregnancy; 
Paternal ITS – father smoked at all during the pregnancy; Postnatal smoke exposure only- no 
maternal in utero tobacco smoke exposure, but postnatal smoke exposure in the home. 
 
 
Supplementary Table 2: GST polymorphisms and lung function from 6 to 24 
years 
 
 Mean FEV1 % 
predicted 
Mean FVC% 
predicted 
Mean FEF25-
75% 
% predicted 
Mean 
FEV1/FVC 
%predicted 
GSTT1 null 100.45 
(96.68 – 104.21) 
98.91 
(94.43 – 103.39) 
98.17 
(92.47 – 103.87) 
100.57 
(98.34 – 102.8) 
GSTT1 non-
null 
101.52 
(99.61 – 103.43) 
101.37 
(99.61 – 103.14) 
94.59 
(91.28 – 97.9) 
99.31 
(98.3-100.31) 
 p=0.62 p=0.32 p=0.29 
 
p=0.31 
GSTM1 null 100.94 
(98.56 – 103.3) 
100.29 
(98.04 – 102.54) 
95.53 
(91.55 – 99.51) 
99.79 
(98.65 – 100.94) 
GSTM1 non-
null 
101.96 
(99.5 – 104.42) 
102.02 
(99.64 – 104.4) 
94.56 
(90.2 – 98.9) 
99.07 
(97.56 -100.59) 
 p=0.56 p=0.3 p=0.75 p=0.46 
Mean lung function from 6-24 years by GST genotype. % predicted based on GLI reference 
values. Unadjusted values 
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